FCM ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 63 | Idiopathic thrombocytopenic purpura | 1 |
| 222 | Primary nephrotic syndrome | 1 |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 363 / Drugs : 212 - (DrugBank : 43) / Drug target genes : 47 - Drug target pathways : 138
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02967328 (ClinicalTrials.gov) | November 2016 | 16/11/2016 | RP% Measurement by FCM as a Diagnostic Test for ITP | A Multi-Center Prospective Blind Study of RP% Measurement by Flow Cytometry in the Diagnosis of Primary Immune Thrombocytopenia | Immune Thrombocytopenia | Other: RP% Measurement by FCM as a Diagnostic Test for ITP | Shandong University | Jinan Central Hospital;Shandong Qianfoshan Hospital | Recruiting | 18 Years | 75 Years | Both | 500 | N/A | China |
222. Primary nephrotic syndrome
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000037467 | 2020-12-31 | 2020-08-28 | Effect of Tripterygium wilfordii polyglycoside tablets on the inhibition of TM on complement pathway and related inflammatory markers in membranous nephropathy | The complement pathway and related inflammatory factor markers in the treatment of idiopathic membranous nephropathy | idiopathic membranous nephropathy | Gold Standard:Cell hemolysis test;Index test:Immunochemiluminescence (ECL) and flow cytometry (FCM) were used to determine the activity of each complement pathway and the target of complement; Complement hemolysis test is usually used to determine the activity of total complement and single complement component, but it is difficult to be applied to clinical ; | Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine | NULL | Pending | 18 | 80 | Both | Target condition:40;Difficult condition:40 | China |